Bupropion Dextromethorphan Co-Administration Metabolic Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dextromethorphan has limited systemic exposure in extensive metabolizers due to rapid hepatic metabolism, limiting its clinical utility as a single agent for treating neurological disorders and cough.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels, and prolong metabolic lifetime, thereby enhancing therapeutic efficacy and reducing adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered alone, then it can treat cough and neurological disorders, but rapid hepatic metabolism limits systemic exposure and therapeutic efficacy in extensive metabolizers
Solution Approach 1:
The patent introduces bupropion and its metabolites as intermediary substances that mediate between dextromethorphan administration and therapeutic effect. These intermediaries inhibit CYP2D6 enzyme activity, thereby reducing dextromethorphan metabolism and increasing systemic exposure. This resolves the contradiction by adding a mediating substance that protects the primary drug from rapid metabolism.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of dextromethorphan by co-administering bupropion. This alters the metabolism rate and plasma concentration profile, transforming dextromethorphan from a rapidly metabolized drug with limited efficacy into one with sustained therapeutic levels. The parameter change resolves the contradiction between rapid metabolism and therapeutic efficacy.
2Reliability
If dextromethorphan is administered to achieve adequate plasma levels, then therapeutic effect improves, but dosing frequency must be increased and adverse events increase
Solution Approach 1:
The patent achieves continuous therapeutic action by extending the half-life of dextromethorphan through metabolic inhibition. Bupropion maintains dextromethorphan plasma levels within the therapeutic window for extended periods, creating continuous useful action without requiring frequent redosing. This resolves the contradiction between adequate plasma levels and dosing frequency.
3Object-affected harmful factors
If dextromethorphan metabolism is accelerated to clear the drug quickly, then adverse events are reduced, but therapeutic lifetime is shortened
Solution Approach 1:
The patent dynamically adjusts the metabolism rate of dextromethorphan through reversible enzyme inhibition. Bupropion temporarily modulates CYP2D6 activity during the therapeutic period, then allows normal metabolism to resume. This dynamic control resolves the contradiction by temporarily slowing metabolism for therapeutic benefit while ultimately allowing drug clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-administration significantly increases dextromethorphan plasma levels, decreases dextrorphan levels, and improves therapeutic properties, allowing for less frequent dosing without loss of efficacy, and reduces adverse events by inhibiting its metabolism and prolonging its presence in the body.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.